DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,660,700 | +2.7% | 47,000 | -0.7% | 0.92% | +6.3% |
| Q2 2023 | $11,355,625 | -7.8% | 47,315 | -3.1% | 0.87% | -12.4% |
| Q1 2023 | $12,312,179 | -6.0% | 48,850 | -1.0% | 0.99% | -9.7% |
| Q4 2022 | $13,098,765 | +3.6% | 49,351 | +0.8% | 1.10% | -3.4% |
| Q3 2022 | $12,646,000 | +1.7% | 48,961 | -0.2% | 1.14% | +1.5% |
| Q2 2022 | $12,434,000 | -16.1% | 49,046 | -3.0% | 1.12% | -0.2% |
| Q1 2022 | $14,828,000 | -12.5% | 50,549 | -1.9% | 1.12% | -7.7% |
| Q4 2021 | $16,947,000 | +6.5% | 51,510 | -1.4% | 1.21% | -2.3% |
| Q3 2021 | $15,911,000 | +10.4% | 52,262 | -2.7% | 1.24% | +12.8% |
| Q2 2021 | $14,411,000 | +17.1% | 53,702 | -1.8% | 1.10% | +9.4% |
| Q1 2021 | $12,310,000 | +1.5% | 54,692 | +0.2% | 1.01% | -3.6% |
| Q4 2020 | $12,130,000 | +0.9% | 54,606 | -2.2% | 1.04% | -10.9% |
| Q3 2020 | $12,024,000 | +21.8% | 55,841 | -0.0% | 1.17% | +11.5% |
| Q2 2020 | $9,875,000 | +27.3% | 55,844 | -0.4% | 1.05% | +5.2% |
| Q1 2020 | $7,758,000 | -9.3% | 56,051 | +0.5% | 1.00% | +16.3% |
| Q4 2019 | $8,558,000 | +5.9% | 55,761 | -0.3% | 0.86% | -1.8% |
| Q3 2019 | $8,078,000 | +0.7% | 55,929 | -0.3% | 0.88% | +0.2% |
| Q2 2019 | $8,021,000 | +6.4% | 56,123 | -1.7% | 0.87% | +5.9% |
| Q1 2019 | $7,535,000 | +28.3% | 57,073 | +0.2% | 0.82% | +14.3% |
| Q4 2018 | $5,875,000 | -5.2% | 56,969 | -0.1% | 0.72% | +10.6% |
| Q3 2018 | $6,194,000 | +8.7% | 57,006 | -1.3% | 0.65% | +1.2% |
| Q2 2018 | $5,699,000 | +0.3% | 57,756 | -0.4% | 0.64% | -2.4% |
| Q1 2018 | $5,680,000 | +7.0% | 58,011 | +1.5% | 0.66% | +11.8% |
| Q4 2017 | $5,307,000 | +8.1% | 57,171 | -0.1% | 0.59% | +2.1% |
| Q3 2017 | $4,911,000 | +1.6% | 57,251 | -0.1% | 0.58% | -1.9% |
| Q2 2017 | $4,836,000 | -1.7% | 57,301 | -0.4% | 0.59% | -5.1% |
| Q1 2017 | $4,920,000 | +6.2% | 57,525 | -3.4% | 0.62% | +1.1% |
| Q4 2016 | $4,634,000 | -2.0% | 59,530 | -1.3% | 0.62% | -3.5% |
| Q3 2016 | $4,727,000 | -22.9% | 60,307 | -0.7% | 0.64% | -23.6% |
| Q2 2016 | $6,132,000 | +4.6% | 60,717 | -1.7% | 0.83% | +4.0% |
| Q1 2016 | $5,862,000 | +3.3% | 61,796 | +1.1% | 0.80% | +0.5% |
| Q4 2015 | $5,675,000 | +9.3% | 61,101 | +0.3% | 0.80% | +5.4% |
| Q3 2015 | $5,192,000 | +0.7% | 60,933 | +1.2% | 0.76% | +10.7% |
| Q2 2015 | $5,154,000 | -2.1% | 60,222 | -2.9% | 0.68% | -7.4% |
| Q1 2015 | $5,263,000 | -22.3% | 61,990 | -21.5% | 0.74% | -17.6% |
| Q4 2014 | $6,770,000 | +13.9% | 78,998 | +1.0% | 0.90% | +9.1% |
| Q3 2014 | $5,943,000 | -4.8% | 78,214 | -1.3% | 0.82% | -4.0% |
| Q2 2014 | $6,241,000 | +2.3% | 79,284 | -2.5% | 0.86% | -1.4% |
| Q1 2014 | $6,101,000 | +0.3% | 81,343 | +3.2% | 0.87% | -4.9% |
| Q4 2013 | $6,083,000 | +7.8% | 78,793 | -3.2% | 0.91% | -1.2% |
| Q3 2013 | $5,645,000 | +12.1% | 81,420 | +2.3% | 0.92% | +6.8% |
| Q2 2013 | $5,037,000 | – | 79,558 | – | 0.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |